Compounds / Metabolic / Retatrutide

Retatrutide

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist — LY3437943)
MetabolicExtensively StudiedFDA: Not approved; Phase III trials ongoing

Overview

Phase II NEJM 2023: up to 24.2% body weight reduction at 12 mg/week — highest reported for any single agent. Phase III ongoing (NCT05929261). Not yet approved.

Mechanism of Action

Triple agonism at GLP-1R + GIPR + glucagon receptor. Glucagon receptor adds energy expenditure and hepatic fat reduction beyond dual agonism. Possible superior weight loss ceiling.

Pharmacokinetics

Half-life
6 days
Peak (Tmax)
1 day
Cleared
~30 days

Molecular Profile

Molecular weight
4,731.33 Da
Type
Triple GLP-1/GIP/glucagon agonist
Length
39 amino acids
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-

Key Research Findings

~24% weight loss at 12 mg/week (Phase II); superior hepatic fat reduction; Phase III ongoing.

Published Research

NEJM (2023)
Retatrutide Phase II: up to 24.2% body weight reduction
View source

Related Metabolic Compounds

SemaglutideTirzepatideCagrilintideMazdutideBioglutideAOD-9604
Clinical Guidance

Research data is not a treatment plan. If you are considering Retatrutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Retatrutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals